Britain's Vectura collaborates with Janssen in asthma, COPD

LONDON (Reuters) - Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday. The collaboration will kick off with the development of a drug candidate for intermediate Phase II clinical trials, the British company said. Janssen, a unit of Johnson & Johnson, will then use Vectura's dry powder inhaler technologies in the development of inhaled therapeutics for airways-related diseases such as asthma, a market worth in excess of $46 billion worldwide, Vectura said. ...



via Health News Headlines - Yahoo News http://ift.tt/1Akx6i3